-
Science Saturday: Biomanufacturing 101 — Understanding a new era of therapeutics
Share this:
Advancing cellular discoveries from clinical trials to commercial therapy is a cornerstone of Mayo Clinic's strategic emphasis on biomanufacturing. The long-term vision is to provide new cures for patients with unmet needs.
"Biomanufacturing is a type of manufacturing that utilizes sources from the human body — cells, blood, enzymes, tissues, genes or genetically engineered cells for use in medicines. We call these biologics," says Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics. "Biologics become a living drug within the body aimed at continually healing damaged tissues and cells." Dr. Allickson is also the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Medicine.
Biomanufacturing next-generation drugs
Biomanufacturing could usher in a new era of biologically based medicines that show hope of going beyond available complex molecule-based drugs to treat illness.
These next-generation biotherapeutics derived from living organisms show potential to:
- Target specific cells or tissues needing repair.
- Trigger fewer adverse effects.
- Personalize therapies for conditions that previously had no known treatments.
- Enable large-scale manufacturing in a cost-effective manner.
The Center for Regenerative Biotherapeutics is seeking to create the world's most advanced ecosystem for biomanufacturing new biotherapeutics, bringing together physicians, scientists, process development experts, high-tech facilities and industry collaborators to test and license first-of-their-kind biologics.
Read the rest of the article on the Center for Regenerative Biotherapeutics blog.
____________________________________________
Other Mayo Clinic medical research websites:
- Research at Mayo Clinic
- Discovery’s Edge
- Advancing the Science
- Mayo Clinic Laboratories
- Forefront
- Center for Individualized Medicine
- Center for the Science of Health Care Delivery
- Mayo Clinic Cancer Center
Share this:
Related articles
ROCHESTER, Minn. — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of ...
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...
With age, cells can experience senescence, a state where they stop growing but continue releasing inflammatory and tissue-degrading molecules. When a person is young, the ...